MPO and acute myeloid leukemia: BPDCN is currently distinguished from AML using positive markers, such as: CD4, CD56, CD123, and TCL1, TCF-4, and CD303; and negative markers: CD3, CD8, CD13, CD19, CD34, and myeloperoxidase (MPO)9.